- Home
- TRNR vs RDHL Comparison
TRNR vs RDHL Comparison
Compare TRNR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | RDHL |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRNR | RDHL |
|---|---|---|
| Price | $1.09 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 101.7K | ★ 1.3M |
| Earning Date | 11-14-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,774,000.00 | $9,550,000.00 |
| Revenue This Year | $249.54 | $381.91 |
| Revenue Next Year | $304.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.36 | 157.62 |
| 52 Week Low | $0.83 | $0.91 |
| 52 Week High | $39.60 | $6.80 |
Technical Indicators
Market Signals| Indicator | TRNR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.76 | 66.52 |
| Support Level | $0.83 | $0.91 |
| Resistance Level | $1.50 | $1.42 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 28.99 | 96.14 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.